HEALTH

An entire endcap of nothing but hand sanitizer

BY Michael Johnsen

When’s the last time an entire endcap has been dedicated against hand sanitizer?

That’s the power of the novel H1N1 pandemic flu that will be returning to a school/workplace near you this fall. What are the chances this endcap will be rampant with empty spaces after the first few months of the season?

Probably not pretty good, but only because CVS will likely fill that space with something else. Even with a heightened retail focus around sanitizers this year, the demand on hand sanitizers may just be that great.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

HEALTH

Special delivery: Walmart expands mail offering

BY Drug Store News Team

NEW YORK Walmart isn’t letting the lack of a physical presence in select Midwestern and Northeastern markets hinder its ability to offer prescription drugs, thanks to the expansion of a mail-order program begun earlier this year in Michigan. The program enables customers to receive a 90-day supply of approximately 300 generics for $10 via free mail delivery, or any of approximately 3,000 other pharmaceuticals that the company offers.

 

“Americans deserve access to quality, affordable health care and medications, yet some families today aren’t filling prescriptions because of high costs or lack of health insurance,” said Dr. John Agwunobi, SVP and president of Walmart’s health and wellness division. “Walmart strives to find innovative new pharmacy solutions that better serve all of our customers’ needs, which is why we’re so excited to offer this program to even more Americans. With this program, we’re able to provide our customers in every rural town or big city across the Midwest and Northeast with more affordable prescription medicines through a convenient, free mail delivery system.”

 

 

In a swipe at some of its competitors, Walmart noted that its program has no gimmicks, membership requirements or enrollment fees, and it’s part of the company’s ongoing commitment to help people save money on prescriptions, regardless of whether they live close to a Walmart pharmacy location.

 

 

States affected by expansion of the Michigan mail-order program include: Connecticut, Delaware, Illinois, Indiana, Iowa, Kentucky, Maine, Maryland, Massachusetts, Minnesota, New Hampshire, New Jersey, New York, North Dakota, Ohio, Pennsylvania, Rhode Island, Tennessee, Vermont, Virginia, Washington DC, West Virginia and Wisconsin.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

HEALTH

Teva launches ‘Patient First’ project

BY Alaric DeArment

NEW YORK Most consumers may not know a lot about biosimilar equivalence, immunogenicity or what “monoclonal antibody” means, but they know that battling a chronic disease can be a frightening and financially devastating prospect. Teva’s new TV campaign is a very sobering reminder of what many already know at a time when all of America is focused on fixing health care.

 

On one end of the continuum of prescription drug prices lies generic drugs purchased under one of the growing number of generic discount programs offered by retailers for less than $50 a year. On the other end lies biotech drugs that can cost nearly half a million dollars a year.

 

 

This is a reminder to politicians and voters that for many patients, manageable diseases carry unmanageable costs. This especially is true for such diseases as cancer, multiple sclerosis and paroxysmal nocturnal hemoglobinuria. Rob Day, one of the patients profiled in the “Patient First” campaign — itself a part of the broader Year of Affordable Healthcare campaign — was diagnosed with PNH at age 19 and must pay $389,000 a year for biotech drugs to treat it.

 

 

While $389,000 is an extreme example, most biotech drugs remain incredibly expensive: A year’s supply of Genentech’s breast cancer drug Herceptin (trastuzumab) costs about $40,000, while a single vial of Elan Corp.’s multiple sclerosis drug Tysabri (natalizumab) costs more than $2,000. Setting up a regulatory environment that allows expensive biotech drugs to face competition from biosimilars would help to alleviate the fears and financial strain of some patients living with chronic illnesses.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES